NYKODE THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.54 NOK | -2.26% |
|
-8.33% | -41.40% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.83
NOK
Average target price
43
NOK
Spread / Average Target
+235.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.40% | 380M | |
| -3.24% | 102B | |
| +2.55% | 96.84B | |
| -0.44% | 21.48B | |
| -18.50% | 20.82B | |
| -7.45% | 18.6B | |
| -40.70% | 16.81B | |
| -25.70% | 13.78B | |
| +0.94% | 13.4B | |
| +22.73% | 11.06B |
- Stock Market
- Equities
- VACC Stock
- News Nykode Therapeutics
- Vaccibody : to Continue Patient Enrollment in Cancer Vaccine Study
